Eureka Therapeutics Announces New England Journal of Medicine Publication of Clinical Study Demonstrating GPRC5D as an Active Target for the Treatment

EMRYVIL, CA–(BUSINESS WIRE)– Eureka Therapeutics, a clinical-stage biotechnology company developing novel T-cell therapies for cancer treatment, today announced the publication of a study in New England Journal of Medicine Titled “GPRC5D Target Vehicle T Cells for Myeloma.” The study was led by Dr. Eric Smith of the Dana-Farber Cancer Institute, Dr. Renee Brintgens of the Roswell Park Comprehensive Cancer Center, and Dr. Sham Melancudi of Memorial Sloan Kettering Cancer Center (MSK).

The GPRC5D binder used in the study was developed by Eureka using its E-ALPHA® platform in collaboration with MSK. Eureka and MSK licensed the link to Juno Therapeutics/Bristol Myers Squib in 2016 for use in CAR, and to Sanofi in 2021 for non-CAR use.

Read:Alternative Medicine Theatre presents ‘Once Upon a Time in Pantoland’ – Photo 1 of 1

While chimeric antigen receptor (CAR)-directed B-cell maturity (BCMA) antigen (CAR) treatments elicited T-cell treatments elicited responses in patients with multiple myeloma, relapses associated with low to negative expression of BCMA are common. Preclinical studies have demonstrated the efficacy of protein-coupled receptor G, class C, group 5, member D (GPRC5D)-CAR T-targeted T-cell therapy in multiple myeloma, including BCMA antigen escape models (Smith EL et al. Science Trans Med 2019) .

In this study, 17 patients were enrolled and received GPRC5D CAR T-cell (MCARH109) therapy, including patients who had previously received BCMA therapies. At the highest dose level (450 million CAR T cells), one patient had grade IV cytokine release syndrome and neurotoxicity, and two patients had cerebellar-like toxicity; There were no treatment-related deaths. The maximum allowable dose has been set at 150 million T cells. A response was reported in 71% of patients in the entire group, and in 58% of those who received doses below 25 million to 150 million cells. Patients who previously relapsed after BCMA-targeted T-cell therapy responded similarly to those of the CAR-naive.

Read:Medical Compass: How can we live well into our 90s?

“The data confirms GPRC5D as an effective target for immunotherapy in multiple myeloma,” said Eric Smith, MD, PhD, and co-inventor of CARs to target multiple myeloma. “We look forward to developing this program either as a stand-alone treatment or as a combined treatment with BCMA targeting CARs.”

“We are pleased to publish the results of the CD28/4-1BB CAR positive-guided GPRC5D-guided study in such a prestigious journal,” said Dr. Cheng Liu, President and CEO of Eureka Therapeutics. “The results underscore our commitment to developing the next generation of safer and more effective T-cell therapies for treating cancer patients.”


Eureka Therapeutics, Inc. is a private clinical-stage biotechnology company focused on developing novel T-cell therapies to treat cancers. Its core technology centers around its ARTEMIS® cell receptor platform and E-ALPHA® antibody discovery platform for the discovery and development of potentially safer and more effective T-cell therapies for the treatment of solid tumors and hematological malignancies. The company currently has two clinical programs, ET140203 (adult ARYA1 and pediatric ARYA2) and ECT204 (ARYA3), in phase I/II US trials in patients with advanced liver cancer.

Read:What Is an Oncologist? | Types of Oncology Specialists

The headquarters of Eureka Therapeutics, Inc. in the San Francisco Bay Area. For more information about Eureka, please visit


Eureka Therapeutics Inc.

Natalie Liu

Investor Relations


[email protected]

Copyright © acrofan / Business Wire All rights reserved

Previous post
A crisis like this creates no shortage of ways to make money
Next post
Paul Warne: Will getting Derby County promotion make Rams boss a League One guru?